Ascendiant Capital Markets Predicts ATOS Q1 Earnings

Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Analysts at Ascendiant Capital Markets issued their Q1 2026 EPS estimates for Atossa Therapeutics in a research note issued on Sunday, April 20th. Ascendiant Capital Markets analyst E. Woo expects that the company will post earnings per share of ($0.06) for the quarter. Ascendiant Capital Markets has a "Buy" rating and a $7.25 price objective on the stock. The consensus estimate for Atossa Therapeutics' current full-year earnings is ($0.22) per share. Ascendiant Capital Markets also issued estimates for Atossa Therapeutics' Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS and Q4 2026 earnings at ($0.06) EPS.

Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last issued its earnings results on Tuesday, March 25th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01.

Separately, HC Wainwright reissued a "buy" rating and issued a $7.00 price target on shares of Atossa Therapeutics in a research report on Wednesday, March 26th.

Atossa Therapeutics Stock Performance

Shares of Atossa Therapeutics stock opened at $0.66 on Wednesday. Atossa Therapeutics has a 52 week low of $0.55 and a 52 week high of $1.81. The stock has a 50 day moving average price of $0.71 and a two-hundred day moving average price of $0.99. The stock has a market capitalization of $85.69 million, a PE ratio of -3.02 and a beta of 1.46.

Hedge Funds Weigh In On Atossa Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC lifted its holdings in shares of Atossa Therapeutics by 280.9% in the third quarter. Barclays PLC now owns 167,718 shares of the company's stock valued at $255,000 after purchasing an additional 123,683 shares in the last quarter. State Street Corp lifted its stake in Atossa Therapeutics by 4.2% during the 3rd quarter. State Street Corp now owns 1,732,221 shares of the company's stock valued at $2,633,000 after acquiring an additional 69,180 shares in the last quarter. Geode Capital Management LLC lifted its stake in Atossa Therapeutics by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,814,446 shares of the company's stock valued at $4,278,000 after acquiring an additional 44,762 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Atossa Therapeutics by 177.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 149,642 shares of the company's stock worth $227,000 after acquiring an additional 95,643 shares in the last quarter. Finally, SG Americas Securities LLC raised its holdings in shares of Atossa Therapeutics by 148.2% in the fourth quarter. SG Americas Securities LLC now owns 103,865 shares of the company's stock valued at $98,000 after purchasing an additional 62,016 shares during the last quarter. Institutional investors and hedge funds own 12.74% of the company's stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.